ORAI1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7923	0.54	11/20
SCHEMBL722456	1.00	9/20
SCHEMBL722661	1.00	9/20
SCHEMBL181689	0.85	9/20
SCHEMBL7734	0.48	9/20
SCHEMBL721220	0.69	8/20
SCHEMBL720496	0.64	8/20
SCHEMBL182078	0.64	8/20
SCHEMBL182143	0.58	8/20
SCHEMBL182731	0.66	7/20
SCHEMBL440892	0.61	7/20
SCHEMBL979962	0.57	7/20
SCHEMBL767634	0.55	7/20
Diphenyl Borinic Acid (SCHEMBL40601)	1.00	6/20
SCHEMBL720890	0.62	6/20
SCHEMBL450945	0.61	6/20
Hydrochloric Acid (SCHEMBL449732)	0.60	6/20
SCHEMBL724582	0.59	6/20
SCHEMBL182281	0.57	6/20
SCHEMBL182055	0.57	6/20

Clinical trials — most relevant to ORAI1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism	PHASE4	COMPLETED
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
The Re-Prosper HF Study	PHASE2/PHASE3	COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.	PHASE2	NOT_YET_RECRUITING
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival	PHASE1	UNKNOWN
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer	PHASE1	RECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS	nan	RECRUITING
Calcium Handling and Epicardial Ablation	nan	COMPLETED
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential	nan	NOT_YET_RECRUITING
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis	nan	UNKNOWN
Predicting Pancreatic Necrosis Using mitDNA	nan	UNKNOWN
Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis	nan	COMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions	nan	COMPLETED
Carnosine Supplementation on Quantity/Quality of Oral Salivae.	nan	UNKNOWN
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure	nan	UNKNOWN
Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children	nan	COMPLETED
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines	nan	UNKNOWN
Magnesium and Vitamin D Combination for Post-COVID Syndrome	nan	COMPLETED
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
The Energetic Origin of Neurodegeneration in MS	nan	COMPLETED
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
Oxidative Stress in Women Treated With Atosiban for Impending Preterm Birth	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ORAI1 binder may also engage these)

Protein	Name	Similarity
Q8BWG9	—	1.000	Q8BWG9 →
Q5M848	—	1.000	Q5M848 →
Q6P8G8	—	0.992	Q6P8G8 →
ORAI3	Protein orai-3 (Transmembrane protein 142C)	0.986	landscape →
Q6AXR8	—	0.985	Q6AXR8 →
Q5EAU0	—	0.983	Q5EAU0 →
ORAI2	Protein orai-2 (CAP-binding protein complex-i	0.981	landscape →
Q8BH10	—	0.980	Q8BH10 →
Q6NZI6	—	0.976	Q6NZI6 →
Q5ZLW2	—	0.973	Q5ZLW2 →
Q5ZL05	—	0.972	Q5ZL05 →
Q6TLE6	—	0.970	Q6TLE6 →
Q5RH73	—	0.964	Q5RH73 →
Q5ZKN3	—	0.963	Q5ZKN3 →
Q5GH76	—	0.962	Q5GH76 →
Q5GH73	—	0.962	Q5GH73 →
Q86W33	—	0.962	Q86W33 →
B3DJK0	—	0.962	B3DJK0 →
Q6P4P2	—	0.961	Q6P4P2 →
Q8CB19	—	0.960	Q8CB19 →
Q68DH5	—	0.959	Q68DH5 →
SYVN1	E3 ubiquitin-protein ligase synoviolin	0.959	landscape →
Q8CB44	—	0.959	Q8CB44 →
Q49LS4	—	0.958	Q49LS4 →
Q791F6	—	0.958	Q791F6 →
Q5XPI4	—	0.957	Q5XPI4 →
Q80U28	—	0.957	Q80U28 →
Q8WXG6	—	0.957	Q8WXG6 →
Q4R512	—	0.957	Q4R512 →
P51593	—	0.956	P51593 →